AKER - Akers' potential merger partner MyMD nabs additional U.S. patents

Akers Biosciences' ([[AKER]] +2.5%) proposed merger partner MyMD Pharmaceutical has been issued US Patent No. 10,835,523 B2, covering method of regulating tumor necrosis factor-alpha for cancers, autoimmune and other disorders associated with chronic inflammation, by USPTO. The patent is a continuation of U.S. patent application No. 15/558,094, which was granted with claims for treating diabetes.The issuance is the ninth granted patent for MYMD-1, with an additional 20 applications currently pending worldwide.As previously announced, Akers Biosciences and MyMD Pharmaceuticals agreed to merge as one to focus on developing and commercializing MyMD’s immunotherapy pipeline assets.

For further details see:

Akers’ potential merger partner MyMD nabs additional U.S. patents